Clinical Psychopharmacology and Neuroscience indexed in CAS, DOI/Crossref, EMBASE, Korea Citation Index (KCI), KoreaMed, Korea Medical Citation Index (KoMCI), PubMed, PubMed Central (PMC), SCOPUS, SCI-expanded (SCIE), and Google Scholar:eISSN 2093-4327 pISSN 1738-1088

Cited by CrossRef (110)

  1. Leen Magarbeh, Claudia Hassel, Maximilian Choi, Farhana Islam, Victoria S. Marshe, Clement C. Zai, Rayyan Zuberi, Roseann S. Gammal, Xiaoyu Men, Maike Scherf‐Clavel, Dietmar Enko, Benicio N. Frey, Roumen Milev, Claudio N. Soares, Sagar V. Parikh, Franca Placenza, Stephen C. Strother, Stefanie Hassel, Valerie H. Taylor, Francesco Leri, Pierre Blier, Faranak Farzan, Raymond W. Lam, Gustavo Turecki, Jane A. Foster, Susan Rotzinger, Stefan Kloiber, James L. Kennedy, Sidney H. Kennedy, Chad A. Bousman, Daniel J. Müller. ABCB1 Gene Variants and Antidepressant Treatment Outcomes: A Systematic Review and Meta‐Analysis Including Results from the CAN‐BIND‐1 Study. Clin Pharma and Therapeutics 2023;114:88
    https://doi.org/10.1002/cpt.2854
  2. Marin Jukic, Filip Milosavljević, Espen Molden, Magnus Ingelman-Sundberg. Pharmacogenomics in treatment of depression and psychosis: an update. Trends in Pharmacological Sciences 2022;43:1055
    https://doi.org/10.1016/j.tips.2022.09.011
  3. . Schatzberg’s Manual of Clinical Psychopharmacology. 2022.
    https://doi.org/10.1176/appi.books.9798894551289.cd13
  4. Dan V. Iosifescu. Pharmacogenomic Testing for Next-Step Antidepressant Selection. JAMA 2022;328:146
    https://doi.org/10.1001/jama.2022.10018
  5. Mark W. Miller. Leveraging genetics to enhance the efficacy of PTSD pharmacotherapies. Neuroscience Letters 2020;726:133562
    https://doi.org/10.1016/j.neulet.2018.04.039
  6. Jeffrey J. Sutherland, Thomas M. Daly, Karen Jacobs, Elias A. Khawam, Leo Pozuelo, Ryan D. Morrison, Stephen B. Milne, J. Scott Daniels, Timothy P. Ryan. Medication Exposure in Highly Adherent Psychiatry Patients. ACS Chem. Neurosci. 2018;9:555
    https://doi.org/10.1021/acschemneuro.7b00375
  7. Mehdi Najafzadeh, Jorge A. Garces, Alejandra Maciel. Economic Evaluation of Implementing a Novel Pharmacogenomic Test (IDgenetix®) to Guide Treatment of Patients with Depression and/or Anxiety. PharmacoEconomics 2017;35:1297
    https://doi.org/10.1007/s40273-017-0587-0
  8. Chiara Fabbri, Ladislav Hosak, Rainald Mössner, Ina Giegling, Laura Mandelli, Frank Bellivier, Stephan Claes, David A. Collier, Alejo Corrales, Lynn E. Delisi, Carla Gallo, Michael Gill, James L. Kennedy, Marion Leboyer, Amanda Lisoway, Wolfgang Maier, Miguel Marquez, Isabelle Massat, Ole Mors, Pierandrea Muglia, Markus M. Nöthen, Michael C. O’Donovan, Jorge Ospina-Duque, Peter Propping, Yongyong Shi, David St Clair, Florence Thibaut, Sven Cichon, Julien Mendlewicz, Dan Rujescu, Alessandro Serretti. Consensus paper of the WFSBP Task Force on Genetics: Genetics, epigenetics and gene expression markers of major depressive disorder and antidepressant response. The World Journal of Biological Psychiatry 2017;18:5
    https://doi.org/10.1080/15622975.2016.1208843
  9. Joseph R. Boland, Brenna Duffy, Nicole M. Myer. Clinical utility of pharmacogenetics-guided treatment of depression and anxiety. Personalized Medicine in Psychiatry 2018;7-8:7
    https://doi.org/10.1016/j.pmip.2017.11.001
  10. Chad Bousman, Josiah Allen, Harris A. Eyre. Pharmacogenetic Tests in Psychiatry. AJP 2018;175:189
    https://doi.org/10.1176/appi.ajp.2017.17101086
  11. Allison B Chambliss, Mark A Marzinke. Clinical Pharmacogenetics for Precision Medicine: Successes and Setbacks. 2018;3:474
    https://doi.org/10.1373/jalm.2017.023127
  12. Chiara Fabbri, Concetta Crisafulli, Marco Calabrò, Edoardo Spina, Alessandro Serretti. Progress and prospects in pharmacogenetics of antidepressant drugs. Expert Opinion on Drug Metabolism & Toxicology 2016;12:1157
    https://doi.org/10.1080/17425255.2016.1202237
  13. Gesche Jürgens, Stig E. Andersen, Henrik B. Rasmussen, Thomas Werge, Heidi D. Jensen, Benjamin Skov Kaas-Hansen, Merete Nordentoft. Effect of Routine Cytochrome P450 2D6 and 2C19 Genotyping on Antipsychotic Drug Persistence in Patients With Schizophrenia. JAMA Netw Open 2020;3:e2027909
    https://doi.org/10.1001/jamanetworkopen.2020.27909
  14. Zane Zeier, Linda L. Carpenter, Ned H. Kalin, Carolyn I. Rodriguez, William M. McDonald, Alik S. Widge, Charles B. Nemeroff. Clinical Implementation of Pharmacogenetic Decision Support Tools for Antidepressant Drug Prescribing. AJP 2018;175:873
    https://doi.org/10.1176/appi.ajp.2018.17111282
  15. Tanja Maria Brückl, Manfred Uhr. ABCB1 Genotyping in the Treatment of Depression . Pharmacogenomics 2016;17:2039
    https://doi.org/10.2217/pgs.16.18
  16. Filippo Corponi, Chiara Fabbri, Alessandro Serretti. Pharmacogenetics and Depression: A Critical Perspective. Psychiatry Investig 2019;16:645
    https://doi.org/10.30773/pi.2019.06.16
  17. George Gillett, Anneka Tomlinson, Orestis Efthimiou, Andrea Cipriani. Predicting treatment effects in unipolar depression: A meta-review. Pharmacology & Therapeutics 2020;212:107557
    https://doi.org/10.1016/j.pharmthera.2020.107557
  18. Abdullah Al Maruf, Chad A. Bousman. Approaches and hurdles of implementing pharmacogenetic testing in the psychiatric clinic. PCN Reports 2022;1
    https://doi.org/10.1002/pcn5.26
  19. Carin A.T.C. Lunenburg, Christiane Gasse. Pharmacogenetics in psychiatric care, a call for uptake of available applications. Psychiatry Research 2020;292:113336
    https://doi.org/10.1016/j.psychres.2020.113336
  20. Boadie W. Dunlop. Pharmacogenetic Decision Support Tools: A Component of Precision Medicine for Psychiatry?. FOC 2017;15:3s
    https://doi.org/10.1176/appi.focus.154S03
  21. Sara Palumbo, Veronica Mariotti, Silvia Pellegrini. A Narrative Review on Pharmacogenomics in Psychiatry. J Clin Psychopharmacol 2024;44:49
    https://doi.org/10.1097/JCP.0000000000001795
  22. Chiara Fabbri, Alessandro Serretti. Understanding Depression. 2024.
    https://doi.org/10.1007/978-981-10-6580-4_1
  23. Ilya Nikolaevich Rozochkin, Mikhail Sergeevich Zastrozhin, Valentin Yurievich Scriabin , Natalya Vladimirovna Sannikova, Anastasiya Valerievna Apenysheva, Elena Vladimirovna Nesterenko, Valentina Aleksandrovna Ivanchenko, Sergey Aleksandrovich Pozdnyakov, Evgeniy Alekseevich Brun, Sychev Dmitriy Alekseevich Sychev Dmitriy Alekseevich. Meta-analysis of pharmacogenetic decision support systems used in psychiatry. Bulletin of Neurology, Psychiatry and Neurosurgery 2021:860
    https://doi.org/10.33920/med-01-2111-05
  24. Matthew L. Baum, Alik S. Widge, Linda L. Carpenter, William M. McDonald, Bruce M. Cohen, Charles B. Nemeroff. Pharmacogenomic Clinical Support Tools for the Treatment of Depression. AJP 2024;181:591
    https://doi.org/10.1176/appi.ajp.20230657
  25. Joshua D. Rosenblat, Yena Lee, Roger S. McIntyre. The effect of pharmacogenomic testing on response and remission rates in the acute treatment of major depressive disorder: A meta-analysis. Journal of Affective Disorders 2018;241:484
    https://doi.org/10.1016/j.jad.2018.08.056
  26. Chad A. Bousman, Daniel J. Müller, Chee H. Ng, Keith Byron, Michael Berk, Ajeet B. Singh. Concordance between actual and pharmacogenetic predicted desvenlafaxine dose needed to achieve remission in major depressive disorder. 2017;27:1
    https://doi.org/10.1097/FPC.0000000000000253
  27. Antonio Del Casale, Leda Marina Pomes, Luca Bonanni, Federica Fiaschè, Clarissa Zocchi, Alessio Padovano, Ottavia De Luca, Gloria Angeletti, Roberto Brugnoli, Paolo Girardi, Robert Preissner, Marina Borro, Giovanna Gentile, Maurizio Pompili, Maurizio Simmaco. Pharmacogenomics-Guided Pharmacotherapy in Patients with Major Depressive Disorder or Bipolar Disorder Affected by Treatment-Resistant Depressive Episodes: A Long-Term Follow-Up Study. JPM 2022;12:316
    https://doi.org/10.3390/jpm12020316
  28. Xenia Gonda, Peter Petschner, Nora Eszlari, Daniel Baksa, Andrea Edes, Peter Antal, Gabriella Juhasz, Gyorgy Bagdy. Genetic variants in major depressive disorder: From pathophysiology to therapy. Pharmacology & Therapeutics 2019;194:22
    https://doi.org/10.1016/j.pharmthera.2018.09.002
  29. Chad A. Bousman, Malcolm Forbes, Mahesh Jayaram, Harris Eyre, Charles F. Reynolds, Michael Berk, Malcolm Hopwood, Chee Ng. Antidepressant Prescribing in the Precision Medicine Era: a Prescriber's Primer on Pharmacogenetic Tools. FOC 2018;16:219
    https://doi.org/10.1176/appi.focus.16204
  30. Y.W. Francis Lam. Comprehensive Pharmacology. 2018.
    https://doi.org/10.1016/B978-0-12-820472-6.00142-0
  31. Douglas A. Drossman, Jan Tack, Alexander C. Ford, Eva Szigethy, Hans Törnblom, Lukas Van Oudenhove. Neuromodulators for Functional Gastrointestinal Disorders (Disorders of Gut−Brain Interaction): A Rome Foundation Working Team Report. Gastroenterology 2018;154:1140
    https://doi.org/10.1053/j.gastro.2017.11.279
  32. Roos van Westrhenen, Katherine J. Aitchison, Magnus Ingelman-Sundberg, Marin M. Jukić. Pharmacogenomics of Antidepressant and Antipsychotic Treatment: How Far Have We Got and Where Are We Going?. Front. Psychiatry 2020;11
    https://doi.org/10.3389/fpsyt.2020.00094
  33. Roy H. Perlis, Daniel Dowd, Maurizio Fava, Todd Lencz, David S. Krause. Randomized, controlled, participant‐ and rater‐blind trial of pharmacogenomic test‐guided treatment versus treatment as usual for major depressive disorder. Depression and Anxiety 2020;37:834
    https://doi.org/10.1002/da.23029
  34. Gouri Mukerjee, Andrea Huston, Boyko Kabakchiev, Micheline Piquette-Miller, Ron van Schaik, Ruslan Dorfman. User considerations in assessing pharmacogenomic tests and their clinical support tools. npj Genomic Med 2018;3
    https://doi.org/10.1038/s41525-018-0065-4
  35. Víctor Pérez, Ariana Salavert, Jordi Espadaler, Miquel Tuson, Jerónimo Saiz-Ruiz, Cristina Sáez-Navarro, Julio Bobes, Enrique Baca-García, Eduard Vieta, José M. Olivares, Roberto Rodriguez-Jimenez, José M. Villagrán, Josep Gascón, Josep Cañete-Crespillo, Montse Solé, Pilar A. Saiz, Ángela Ibáñez, Javier de Diego-Adeliño, José M. Menchón. Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial. BMC Psychiatry 2017;17
    https://doi.org/10.1186/s12888-017-1412-1
  36. Sanjida Ahmed, Ramzan Tahir, Umbreen Akhtar, Mark Faiz. Pharmacogenomics Guided Prescription Changes Improved Medication Effectiveness in Patients With Mental Health-Related Disability: A Retrospective Cohort Analyses. Front. Genet. 2021;12
    https://doi.org/10.3389/fgene.2021.644694
  37. Maria J. Arranz, Alex Gonzalez-Rodriguez, Josefina Perez-Blanco, Rafael Penadés, Blanca Gutierrez, Laura Ibañez, Barbara Arias, Mercè Brunet, Jorge Cervilla, Juliana Salazar, Rosa Catalan. A pharmacogenetic intervention for the improvement of the safety profile of antipsychotic treatments. Transl Psychiatry 2019;9
    https://doi.org/10.1038/s41398-019-0511-9
  38. Krista N. Bohlen, Julie M. Kittelsrud, Morgan E. Nelson, Lisa K. Weisser, Neil J. Matthiesen, Julie A. Fieldsend, Nicholas B. Buschette, Leslie L. Cooper, Gareth E. Davies, Erik A. Ehli. Clinical utility of pharmacogenetics in a psychiatric and primary care population. Pharmacogenomics J 2023;23:21
    https://doi.org/10.1038/s41397-022-00292-6
  39. Paul Bradley, Michael Shiekh, Vishaal Mehra, Keith Vrbicky, Stacey Layle, Marilyn C. Olson, Alejandra Maciel, Ali Cullors, Jorge A. Garces, Andrew A. Lukowiak. Improved efficacy with targeted pharmacogenetic-guided treatment of patients with depression and anxiety: A randomized clinical trial demonstrating clinical utility. Journal of Psychiatric Research 2018;96:100
    https://doi.org/10.1016/j.jpsychires.2017.09.024
  40. Chad A. Bousman, Boadie W. Dunlop. Genotype, phenotype, and medication recommendation agreement among commercial pharmacogenetic-based decision support tools. Pharmacogenomics J 2018;18:613
    https://doi.org/10.1038/s41397-018-0027-3
  41. Simran Maggo, Martin A. Kennedy, Zoe A. Barczyk, Allison L. Miller, Julia J. Rucklidge, Roger T. Mulder, James A. Foulds. Common CYP2D6, CYP2C9, and CYP2C19 Gene Variants, Health Anxiety, and Neuroticism Are Not Associated With Self-Reported Antidepressant Side Effects. Front. Genet. 2019;10
    https://doi.org/10.3389/fgene.2019.01199
  42. Mary Bunka, Gavin Wong, Dan Kim, Louisa Edwards, Jehannine Austin, Mary M. Doyle-Waters, Andrea Gaedigk, Stirling Bryan. Evaluating treatment outcomes in pharmacogenomic-guided care for major depression: A rapid review and meta-analysis. Psychiatry Research 2023;321:115102
    https://doi.org/10.1016/j.psychres.2023.115102
  43. Michael S. Zastrozhin, Aleksandr S. Sorokin, Tatyana V. Agibalova, Elena A. Grishina, Anastasiya Р. Antonenko, Ilya N. Rozochkin, Denis V. Duzhev, Valentine Y. Skryabin, Tatyana E. Galaktionova, Ilya V. Barna, Anna V. Orlova, Albert D. Aguzarov, Ludmila M. Savchenko, Evgeny A. Bryun, Dmitry A. Sychev. Using a personalized clinical decision support system for bromdihydrochlorphenylbenzodiazepine dosing in patients with anxiety disorders based on the pharmacogenomic markers. Human Psychopharmacology 2018;33
    https://doi.org/10.1002/hup.2677
  44. Chad A Bousman, Malcolm Hopwood. Commercial pharmacogenetic-based decision-support tools in psychiatry. The Lancet Psychiatry 2016;3:585
    https://doi.org/10.1016/S2215-0366(16)00017-1
  45. Jeffrey Rakofsky, Mark Rapaport. Mood Disorders. 2018;24:804
    https://doi.org/10.1212/CON.0000000000000604
  46. Kristen M. Ward, Danielle S. Taubman, Amy L. Pasternak, Kyle J. Burghardt, Vicki L. Ellingrod, Sagar V. Parikh. Teaching psychiatric pharmacogenomics effectively: Evaluation of a novel interprofessional online course. J Am Coll Clin Pharm 2021;4:176
    https://doi.org/10.1002/jac5.1381
  47. Danilo Arnone, Omar Omar, Teresa Arora, Linda Östlundh, Reshma Ramaraj, Syed Javaid, Romona Devi Govender, Bassam R. Ali, George P. Patrinos, Allan H. Young, Emmanuel Stip. Effectiveness of pharmacogenomic tests including CYP2D6 and CYP2C19 genomic variants for guiding the treatment of depressive disorders: Systematic review and meta-analysis of randomised controlled trials. Neuroscience & Biobehavioral Reviews 2023;144:104965
    https://doi.org/10.1016/j.neubiorev.2022.104965
  48. Gabriel R. Fries, Harris A. Eyre, Chad Bousman, Joao Quevedo, Bernhard T. Baune. Pharmacoepigenetics. 2023.
    https://doi.org/10.1016/B978-0-12-813939-4.00027-9
  49. Pratyusha Attaluri, Ayeshah G. Mohiuddin, Kowsar Teymouri, James L. Kennedy. Tasman’s Psychiatry. 2023.
    https://doi.org/10.1007/978-3-030-51366-5_130
  50. Donald D Chang, Harris A Eyre, Ryan Abbott, Michael Coudreaut, Bernhard T Baune, Jeffrey A Shaman, Helen Lavretsky, Eric J Lenze, David A Merrill, Ajeet B Singh, Benoit H Mulsant, Charles F Reynolds, Daniel J Müller, Chad Bousman. Pharmacogenetic Guidelines and Decision Support Tools for Depression Treatment: Application to Late-Life. Pharmacogenomics 2018;19:1269
    https://doi.org/10.2217/pgs-2018-0099
  51. . Schatzberg’s Manual of Psychopharmacology. 2018.
    https://doi.org/10.1176/appi.books.9781615372997.AS13
  52. Beatriz Carvalho Henriques, Esther H. Yang, Diego Lapetina, Michael S. Carr, Vasyl Yavorskyy, Joshua Hague, Katherine J. Aitchison. How Can Drug Metabolism and Transporter Genetics Inform Psychotropic Prescribing?. Front. Genet. 2020;11
    https://doi.org/10.3389/fgene.2020.491895
  53. Y. W. Francis Lam. Pharmacogenomics. 2020.
    https://doi.org/10.1016/B978-0-12-812626-4.00014-0
  54. Chiara Fabbri, Joseph Zohar, Alessandro Serretti. Pharmacogenetic tests to guide drug treatment in depression: Comparison of the available testing kits and clinical trials. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2018;86:36
    https://doi.org/10.1016/j.pnpbp.2018.05.007
  55. Chad A. Bousman, Lisa C. Brown, Ajeet B. Singh, Harris A. Eyre, Daniel J. Müller. Personalized Psychiatry. 2018.
    https://doi.org/10.1016/B978-0-12-813176-3.00036-5
  56. Win Lee Edwin Wong, Chiara Fabbri, Benjamin Laplace, Danyang Li, Roos van Westrhenen, Cathryn M. Lewis, Gavin Stewart Dawe, Allan H. Young. The Effects of CYP2C19 Genotype on Proxies of SSRI Antidepressant Response in the UK Biobank. Pharmaceuticals 2023;16:1277
    https://doi.org/10.3390/ph16091277
  57. Ryan Abbott, Donald D. Chang, Harris A. Eyre, Chad A. Bousman, David A. Merrill, Helen Lavretsky. Pharmacogenetic Decision Support Tools: A New Paradigm for Late-Life Depression?. The American Journal of Geriatric Psychiatry 2018;26:125
    https://doi.org/10.1016/j.jagp.2017.05.012
  58. Theresa R Tonozzi, Glenn D Braunstein, Anja Kammesheidt, Chris Curran, Shahrokh Golshan, John Kelsoe. Pharmacogenetic Profile and Major Depressive and/or Bipolar Disorder Treatment: a Retrospective, Cross-Sectional Study. Pharmacogenomics 2018;19:1169
    https://doi.org/10.2217/pgs-2018-0088
  59. Chiara Fabbri, Alessandro Serretti. Clinical application of antidepressant pharmacogenetics: Considerations for the design of future studies. Neuroscience Letters 2020;726:133651
    https://doi.org/10.1016/j.neulet.2018.06.020
  60. Kristian Kleine Schaars, Roos van Westrhenen. Pharmacogenomics and the Management of Mood Disorders—A Review. JPM 2023;13:1183
    https://doi.org/10.3390/jpm13071183
  61. Pratyusha Attaluri, Ayeshah G. Mohiuddin, Kowsar Teymouri, James L. Kennedy. Tasman’s Psychiatry. 2023.
    https://doi.org/10.1007/978-3-030-42825-9_130-1
  62. Xinrui Wang, Chenfei Wang, Yi Zhang, Zhuoling An. Effect of pharmacogenomics testing guiding on clinical outcomes in major depressive disorder: a systematic review and meta-analysis of RCT. BMC Psychiatry 2023;23
    https://doi.org/10.1186/s12888-023-04756-2
  63. Chad A Bousman, Katarina Arandjelovic, Serafino G Mancuso, Harris A Eyre, Boadie W Dunlop. Pharmacogenetic Tests and Depressive Symptom Remission: A Meta-Analysis of Randomized Controlled Trials. Pharmacogenomics 2019;20:37
    https://doi.org/10.2217/pgs-2018-0142
  64. Kyung Ho Lee, Won-Myong Bahk, Soo-Jung Lee, Alessandro Serretti, Chi-Un Pae. A Practical Utility and Benefit of Pharmacogenetic-based Antidepressant Treatment Strategy for Major Depressive Disorder Patients with Difficult-to-treat. Clin Psychopharmacol Neurosci 2021;19:160
    https://doi.org/10.9758/cpn.2021.19.1.160
  65. Roos van Westrhenen. Clinical Textbook of Mood Disorders. 2021.
    https://doi.org/10.1017/9781108973922.025
  66. J. M. Menchón, J. Espadaler, M. Tuson, J. Saiz-Ruiz, J. Bobes, E. Vieta, E. Álvarez, V. Pérez. Patient characteristics driving clinical utility in psychiatric pharmacogenetics: a reanalysis from the AB-GEN multicentric trial. J Neural Transm 2019;126:95
    https://doi.org/10.1007/s00702-018-1879-z
  67. Gin S Malhi, Darryl Bassett, Philip Boyce, Richard Bryant, Paul B Fitzgerald, Kristina Fritz, Malcolm Hopwood, Bill Lyndon, Roger Mulder, Greg Murray, Richard Porter, Ajeet B Singh. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry 2015;49:1087
    https://doi.org/10.1177/0004867415617657
  68. Adam Jameson, Beth Fylan, Greg C. Bristow, Gurdeep S. Sagoo, Caroline Dalton, Alastair Cardno, Jaspreet Sohal, Samantha L. McLean. What Are the Barriers and Enablers to the Implementation of Pharmacogenetic Testing in Mental Health Care Settings?. Front. Genet. 2021;12
    https://doi.org/10.3389/fgene.2021.740216
  69. M.P. Forbes, P. Jaksa, H.A. Eyre, C. Bousman. Neurobiology of Depression. 2021.
    https://doi.org/10.1016/B978-0-12-813333-0.00030-5
  70. Kyoung-Sae Na, Yong-Ku Kim. Major Depressive Disorder. 2021.
    https://doi.org/10.1007/978-981-33-6044-0_4
  71. Chiara Fabbri, Alessandro Serretti. Genetics of Treatment Outcomes in Major Depressive Disorder: Present and Future. Clin Psychopharmacol Neurosci 2020;18:1
    https://doi.org/10.9758/cpn.2020.18.1.1
  72. Pasquale Paribello, Mirko Manchia, Federica Pinna, Ulker Isayeva, Alessio Squassina, Claudia Pisanu, Lorenzo Balderi, Martina Contu, Marco Pinna, Bernardo Carpiniello. Pharmacokinetic Markers of Clinical Outcomes in Severe Mental Illness: A Systematic Review. IJMS 2023;24:4776
    https://doi.org/10.3390/ijms24054776
  73. Chad A. Bousman, Anita Oomen, Chaten D. Jessel, Rajesh R Tampi, Brent P. Forester, Harris A. Eyre, Helen Lavretsky, Daniel J Müller. Perspectives on the Clinical Use of Pharmacogenetic Testing in Late-Life Mental Healthcare: A Survey of the American Association of Geriatric Psychiatry Membership. The American Journal of Geriatric Psychiatry 2022;30:560
    https://doi.org/10.1016/j.jagp.2021.09.013
  74. Ramzi G. Salloum, Jeffrey R. Bishop, Amanda L. Elchynski, D. Max Smith, Elizabeth Rowe, Kathryn V. Blake, Nita A. Limdi, Christina L. Aquilante, Jill Bates, Amber L. Beitelshees, Amber Cipriani, Benjamin Q. Duong, Philip E. Empey, Christine M. Formea, J. Kevin Hicks, Pawel Mroz, David Oslin, Amy L. Pasternak, Natasha Petry, Laura B. Ramsey, Allyson Schlichte, Sandra M. Swain, Kristen M. Ward, Kristin Wiisanen, Todd C. Skaar, Sara L. Van Driest, Larisa H. Cavallari, Sony Tuteja. Best–worst scaling methodology to evaluate constructs of the Consolidated Framework for Implementation Research: application to the implementation of pharmacogenetic testing for antidepressant therapy. Implement Sci Commun 2022;3
    https://doi.org/10.1186/s43058-022-00300-7
  75. Changsu Han, Sheng-Min Wang, Won-Myong Bahk, Soo-Jung Lee, Ashwin A. Patkar, Prakash S. Masand, Laura Mandelli, Chi-Un Pae, Alessandro Serretti. A Pharmacogenomic-based Antidepressant Treatment for Patients with Major Depressive Disorder: Results from an 8-week, Randomized, Single-blinded Clinical Trial. Clin Psychopharmacol Neurosci 2018;16:469
    https://doi.org/10.9758/cpn.2018.16.4.469
  76. Rustin D. Crutchley, Nicole Keuler. Sub-Analysis of CYP-GUIDES Data: Assessing the Prevalence and Impact of Drug-Gene Interactions in an Ethnically Diverse Cohort of Depressed Individuals. Front. Pharmacol. 2022;13
    https://doi.org/10.3389/fphar.2022.884213
  77. Chad A. Bousman, Malcolm Forbes, Mahesh Jayaram, Harris Eyre, Charles F. Reynolds, Michael Berk, Malcolm Hopwood, Chee Ng. Antidepressant prescribing in the precision medicine era: a prescriber’s primer on pharmacogenetic tools. BMC Psychiatry 2017;17
    https://doi.org/10.1186/s12888-017-1230-5
  78. Michael Zastrozhin, Valentin Skryabin, Alexander Sorokin, Oleg Buzik, Inessa Bedina, Elena Grishina, Kristina Ryzhikova, Valery Shipitsyn, Evgeny Bryun, Dmitry Sychev. Using a pharmacogenetic clinical decision support system to improve psychopharmacotherapy dosing in patients with affective disorders. 2020;35
    https://doi.org/10.1515/dmpt-2019-0033
  79. Farhana Islam, Ilona Gorbovskaya, Daniel J. Müller. Major Depressive Disorder. 2020.
    https://doi.org/10.1007/978-981-33-6044-0_13
  80. Alessandra Minelli, Stefano Barlati, Bernhard T Baune. Evaluating study designs and treatment outcomes of antidepressant pharmacogenetic clinical trials - Challenges and future perspectives. A critical review. European Neuropsychopharmacology 2022;59:68
    https://doi.org/10.1016/j.euroneuro.2022.04.007
  81. Andrea R. Collins, Simon Kung, Jacqueline T. Ho, Jessica A. Wright, Kristina C. Dammen, Emily K. Johnson, Maria I. Lapid, Jonathan G. Leung. Pharmacogenetic testing in psychiatric inpatients with polypharmacy is associated with decreased medication side effects but not via medication changes. Journal of Psychiatric Research 2020;126:105
    https://doi.org/10.1016/j.jpsychires.2020.05.002
  82. Ruslan Dorfman, Zana London, Mark Metias, Boyko Kabakchiev, Gouri Mukerjee, Andrea Moser. Individualized Medication Management in Ontario Long-Term Care Clinical Impact on Management of Depression, Pain, and Dementia. Journal of the American Medical Directors Association 2020;21:823
    https://doi.org/10.1016/j.jamda.2020.04.009
  83. R. van Westrhenen, R. H. N. van Schaik, T. van Gelder, T. K. Birkenhager, P. R. Bakker, E. J. F. Houwink, P. M. Bet, W. J. G. Hoogendijk, M. J. M. van Weelden-Hulshof. Policy and Practice Review: A First Guideline on the Use of Pharmacogenetics in Clinical Psychiatric Practice. Front. Pharmacol. 2021;12
    https://doi.org/10.3389/fphar.2021.640032
  84. Yu Cheng, Hongmei Liu, Ruixue Yuan, Kai Yuan, Shunying Yu. Effectiveness of pharmacogenomics on the response and remission of treatment-resistant depression: a meta-analysis of randomised controlled trials. Gen Psych 2023;36:e101050
    https://doi.org/10.1136/gpsych-2023-101050
  85. James A Foulds, Simran DS Maggo, Martin A Kennedy. Personalised prescribing in psychiatry: Has pharmacogenomics delivered on its promise?. Aust N Z J Psychiatry 2016;50:509
    https://doi.org/10.1177/0004867416640099
  86. Ron H. N. van Schaik, Daniel J. Müller, Alessandro Serretti, Magnus Ingelman-Sundberg. Pharmacogenetics in Psychiatry: An Update on Clinical Usability. Front. Pharmacol. 2020;11
    https://doi.org/10.3389/fphar.2020.575540
  87. Heather D. Anderson, Thida M. Thant, David P. Kao, Kristy R. Crooks, Nicholas D. Mendola, Christina L. Aquilante. Pharmacogenetic testing among patients with depression in a US managed care population. Clinical Translational Sci 2022;15:1644
    https://doi.org/10.1111/cts.13279
  88. Kimberly Peterson, Eric Dieperink, Johanna Anderson, Erin Boundy, Lauren Ferguson, Mark Helfand. Rapid evidence review of the comparative effectiveness, harms, and cost-effectiveness of pharmacogenomics-guided antidepressant treatment versus usual care for major depressive disorder. Psychopharmacology 2017;234:1649
    https://doi.org/10.1007/s00213-017-4622-9
  89. Michael J McCarthy, Yucui Chen, Anna Demodena, Susan G Leckband, Eileen Fischer, Shahrokh Golshan, Trisha Suppes, John R Kelsoe. A prospective study to determine the clinical utility of pharmacogenetic testing of veterans with treatment-resistant depression. J Psychopharmacol 2021;35:992
    https://doi.org/10.1177/02698811211015224
  90. Ajeet B Singh. Psychotropic pharmacogenetics. Aust N Z J Psychiatry 2016;50:596
    https://doi.org/10.1177/0004867416649443
  91. Maria L. Ricardo-Silgado, Sneha Singh, Lizeth Cifuentes, Paul A. Decker, Daniel Gonzalez-Izundegui, Ann M. Moyer, Maria D. Hurtado, Michael Camilleri, Suzette J. Bielinski, Andres Acosta. Association between CYP metabolizer phenotypes and selective serotonin reuptake inhibitors induced weight gain: a retrospective cohort study. BMC Med 2022;20
    https://doi.org/10.1186/s12916-022-02433-x
  92. Filip Milosavljević, Prof. Espen Molden, Prof. Magnus Ingelman-Sundberg, Assoc. Prof. Marin M Jukić. Current level of evidence for improvement of antidepressant efficacy and tolerability by pharmacogenomic-guided treatment: A Systematic review and meta-analysis of randomized controlled clinical trials. European Neuropsychopharmacology 2024;81:43
    https://doi.org/10.1016/j.euroneuro.2024.01.005
  93. Lara E. Murphy, Trehani M. Fonseka, Chad A. Bousman, Daniel J. Müller. Gene-drug pairings for antidepressants and antipsychotics: level of evidence and clinical application. Mol Psychiatry 2022;27:593
    https://doi.org/10.1038/s41380-021-01340-6
  94. Farah Khorassani, Mandy Jermain, Christine Cadiz. Pharmacogenomic Testing to Guide Treatment of Major Depressive Disorder: A Systematic Review. Curr Treat Options Psych 2024;11:123
    https://doi.org/10.1007/s40501-024-00316-x
  95. Ajeet B. Singh, Chad A. Bousman. Antidepressant Pharmacogenetics. AJP 2017;174:417
    https://doi.org/10.1176/appi.ajp.2017.17020173
  96. Silvia Vilches, Miquel Tuson, Eduard Vieta, Enric Álvarez, Jordi Espadaler. Effectiveness of a Pharmacogenetic Tool at Improving Treatment Efficacy in Major Depressive Disorder: A Meta-Analysis of Three Clinical Studies. Pharmaceutics 2019;11:453
    https://doi.org/10.3390/pharmaceutics11090453
  97. John F. Greden, Sagar V. Parikh, Anthony J. Rothschild, Michael E. Thase, Boadie W. Dunlop, Charles DeBattista, Charles R. Conway, Brent P. Forester, Francis M. Mondimore, Richard C. Shelton, Matthew Macaluso, James Li, Krystal Brown, Alexa Gilbert, Lindsey Burns, Michael R. Jablonski, Bryan Dechairo. Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study. Journal of Psychiatric Research 2019;111:59
    https://doi.org/10.1016/j.jpsychires.2019.01.003
  98. Stephen R. Marder, Thomas Laughren, Steven J. Romano. The Importance of Adequately Powered Clinical Studies: Response to Khan et al.. AJP 2018;175:188
    https://doi.org/10.1176/appi.ajp.2017.17091016r
  99. Mary Bunka, Jehannine Austin, Louisa Edwards, Gavin Wong, Stirling Bryan. Regarding the meta-analyses of pharmacogenomics-guided antidepressant treatment: A response to Milosavljevic et al.. European Neuropsychopharmacology 2024;88:51
    https://doi.org/10.1016/j.euroneuro.2024.08.002
  100. Katarina Arandjelovic, Harris A. Eyre, Eric Lenze, Ajeet B. Singh, Michael Berk, Chad Bousman. The role of depression pharmacogenetic decision support tools in shared decision making. J Neural Transm 2019;126:87
    https://doi.org/10.1007/s00702-017-1806-8
  101. Xiaoxiao Shan, Wenli Zhao, Yan Qiu, Haishan Wu, Jindong Chen, Yiru Fang, Wenbin Guo, Lehua Li. Preliminary Clinical Investigation of Combinatorial Pharmacogenomic Testing for the Optimized Treatment of Depression: A Randomized Single-Blind Study. Front. Neurosci. 2019;13
    https://doi.org/10.3389/fnins.2019.00960
  102. N. A. Shnayder, A. V. Kidyaeva, E. E. Vaiman, A. R. Asadullin, M. M. Petrova, D. S. Kaskaeva, G. V. Matyushin, A. A. Evsyukov, E. V. Galko, N. P. Garganeeva, G. A. Chumakova, N. V. Lareva, N. G. Neznanov, R. F. Nasyrova. Role of Pharmacokinetics and Pharmacogenetics of Antidepressant-Induced Prolongation of the QT Interval and Torsade de Pointes in Patients with Mental Disorders. jour 2023;3:72
    https://doi.org/10.52667/2712-9179-2023-3-2-72-119
  103. Valentin Skryabin, Ilya Rozochkin, Mikhail Zastrozhin, Volker Lauschke, Johan Franck, Evgeny Bryun, Dmitry Sychev. Meta-analysis of pharmacogenetic clinical decision support systems for the treatment of major depressive disorder. Pharmacogenomics J 2023;23:45
    https://doi.org/10.1038/s41397-022-00295-3
  104. Douglas F. Levinson. Personalized Psychiatry. 2023.
    https://doi.org/10.1016/B978-0-12-813176-3.00016-X
  105. М.С. Застрожин, А.С. Сорокин, Т.В. Агибалова, И.А. Бедина, Е.А. Гришина, А.П. Антоненко, И.Н. Розочкин, Т.Е. Галактионова, И.В. Барна, В.Ю. Скрябин, А.В. Орлова, А.Д. Агузаров, Л.М. Савченко, Е.А. Брюн, Д.А. Сычев. Expirience of implementation of personalized clinical decision support system for dosing of bromdihydrochlorphenylbenzodiazepine in patients with alcohol withdraw syndrome based on the pharmacogenomic markers. 2020:13
    https://doi.org/10.25557/2073-7998.2019.01.13-24
  106. . .
    https://doi.org/
  107. Antonio Del Casale, Serena Sorice, Alessio Padovano, Maurizio Simmaco, Stefano Ferracuti, Dorian A. Lamis, Chiara Rapinesi, Gabriele Sani, Paolo Girardi, Georgios D. Kotzalidis, Maurizio Pompili. Psychopharmacological Treatment of Obsessive-Compulsive Disorder (OCD). CN 2019;17:710
    https://doi.org/10.2174/1570159X16666180813155017
  108. Lisa C. Brown, Joseph D. Stanton, Kanika Bharthi, Abdullah Al Maruf, Daniel J. Müller, Chad A. Bousman. Pharmacogenomic Testing and Depressive Symptom Remission: A Systematic Review and Meta‐Analysis of Prospective, Controlled Clinical Trials. Clin Pharma and Therapeutics 2022;112:1303
    https://doi.org/10.1002/cpt.2748
  109. . Schatzberg’s Manual of Psychopharmacology. 2022.
    https://doi.org/10.1176/appi.books.9781615372300.AS13
  110. Teuntje A. D. Pelgrim, Alexandra Philipsen, Allan H. Young, Mario Juruena, Ester Jimenez, Eduard Vieta, Marin Jukić, Erik Van der Eycken, Urs Heilbronner, Ramona Moldovan, Martien J. H. Kas, Raj R. Jagesar, Markus M. Nöthen, Per Hoffmann, Noam Shomron, Laura L. Kilarski, Thérèse van Amelsvoort, Bea Campforts, Roos van Westrhenen. A New Intervention for Implementation of Pharmacogenetics in Psychiatry: A Description of the PSY-PGx Clinical Study. Pharmaceuticals 2024;17:151
    https://doi.org/10.3390/ph17020151